Academic Journal
Investigation of the potential of leukoreduction filters in the creation of anti-inflammatory compound.
| Title: | Investigation of the potential of leukoreduction filters in the creation of anti-inflammatory compound. |
|---|---|
| Authors: | Balagholi S; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: saharbalagholi@gmail.com., Dabbaghi R; Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: Dabbaghi1990@gmail.com., Mohammadi S; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Saeedm_58@yahoo.com., Abbasi Malati Z; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. Electronic address: z.abbasi1369@yahoo.com., Javan MR; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. Electronic address: javaneee@gmail.com., Eshghi P; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Pediatric Congenital Hematologic disorders research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. |
| Source: | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2023 Feb; Vol. 62 (1), pp. 103520. Date of Electronic Publication: 2022 Aug 24. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Pergamon Country of Publication: England NLM ID: 101095653 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-0502 (Print) Linking ISSN: 14730502 NLM ISO Abbreviation: Transfus Apher Sci |
| Imprint Name(s): | Original Publication: Oxford : Pergamon : Elsevier Science, c2001- |
| MeSH Terms: | SARS-CoV-2*/metabolism , COVID-19*, Humans ; Cytokines ; Betamethasone/pharmacology ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use |
| Abstract: | Background: Some viruses such as SARS, SARS-CoV-2, and MERS cause an imbalance in immune responses and leads to an acute inflammatory reaction named cytokine storm. In this situation, an anti-inflammatory component can modulate the immune system and decrease mortality. The aim of this study was investigate the potential of leukoreduction filters (LRFs) in creating an anti-inflammatory compound. Materials and Methods: In this experimental study, firstly optimal dose of the anti-inflammatory drug was obtained through LRFs treatment with 0.1 mg, 0.4 mg, 0.6 mg of Betamethasone. Then inflammatory and anti-inflammatory cytokine in gene and protein level was evaluated. In the next step, LRFs were categorized into treatment 1, treatment 2, control assay, and control groups and treated with the optimal dose of the drug. Finally, the obtained compound was investigated for the concentration of IL1, IL6, and TNF-α as inflammatory and IL4, IL1Ra, and IL10 as anti-inflammatory cytokines. Results: The results of the current study showed that the concentration of 0.4 mg of Betamethasone lead to a significant increase of anti-inflammatory cytokine in gene and protein levels. The results also showed that the Betamethasone treated groups (treatment1) causes a significant increase in the secretion of anti-inflammatory cytokine compares to the control while inflammatory cytokine remained at the control level. Conclusion: The results showed that under influence of anti-inflammatory drug treatments the production and secretion of anti-inflammatory cytokines can be induced in LRFs. Competing Interests: Conflict of interest The authors declare that they have no conflict of interest. (Copyright © 2022 Elsevier Ltd. All rights reserved.) |
| References: | J Clin Invest. 2017 Jan 3;127(1):1-4. (PMID: 28045402) Diabetes. 2020 Sep;69(9):1857-1863. (PMID: 32669390) Transfus Med Rev. 1995 Apr;9(2):145-66. (PMID: 7795332) Ther Adv Musculoskelet Dis. 2017 Aug;9(8):183-196. (PMID: 28835778) Nature. 2002 Dec 19-26;420(6917):846-52. (PMID: 12490957) Cytokine. 2020 Sep;133:155143. (PMID: 32460144) Infect Immun. 1994 May;62(5):2046-50. (PMID: 8168970) Expert Opin Investig Drugs. 2000 Jul;9(7):1651-63. (PMID: 11060768) Inflamm Res. 2003 Oct;52(10):404-7. (PMID: 14520515) Neural Regen Res. 2019 Aug;14(8):1335-1342. (PMID: 30964051) J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331. (PMID: 32171193) Nature. 2002 Dec 19-26;420(6917):853-9. (PMID: 12490958) Clin Rheumatol. 2020 Jul;39(7):2085-2094. (PMID: 32474885) J Exp Med. 1992 Aug 1;176(2):593-8. (PMID: 1386877) JAMA Netw Open. 2020 Apr 1;3(4):e205619. (PMID: 32275319) J Clin Immunol. 1994 Jan;14(1):20-30. (PMID: 8132734) Diabetes Res Clin Pract. 2014 Aug;105(2):141-50. (PMID: 24798950) Crit Care. 2020 Jul 9;24(1):413. (PMID: 32646499) Clin Chest Med. 2008 Dec;29(4):617-25, viii. (PMID: 18954697) Am J Physiol. 1997 Dec;273(6):R1885-90. (PMID: 9435641) Cytokine. 2016 May;81:137-41. (PMID: 26994310) Clin Vaccine Immunol. 2013 Mar;20(3):319-27. (PMID: 23283640) Chest. 2000 Apr;117(4):1162-72. (PMID: 10767254) Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. (PMID: 32350134) Acta Biomater. 2017 Apr 15;53:389-398. (PMID: 28159717) Med Drug Discov. 2020 Mar;5:100019. (PMID: 32296777) Cell. 2020 May 28;181(5):1036-1045.e9. (PMID: 32416070) Cell Mol Immunol. 2016 Jan;13(1):3-10. (PMID: 26189369) Vet Clin North Am Equine Pract. 1994 Dec;10(3):535-47. (PMID: 7704817) J Perinatol. 2014 May;34(5):380-5. (PMID: 24526008) Arthritis Res Ther. 2010;12(3):R114. (PMID: 20537160) Front Immunol. 2019 Jun 04;10:1191. (PMID: 31214172) J Virol. 2009 Jul;83(14):7062-74. (PMID: 19420084) |
| Contributed Indexing: | Keywords: Betamethasone; IL1; IL1Ra; Leukoreduction filters; SARA-CoV-2 |
| Substance Nomenclature: | 0 (Cytokines) 9842X06Q6M (Betamethasone) 0 (Anti-Inflammatory Agents) |
| Entry Date(s): | Date Created: 20220917 Date Completed: 20230214 Latest Revision: 20230214 |
| Update Code: | 20230214 |
| PubMed Central ID: | PMC9398560 |
| DOI: | 10.1016/j.transci.2022.103520 |
| PMID: | 36115766 |
| Database: | MEDLINE |
| ISSN: | 1473-0502 |
|---|---|
| DOI: | 10.1016/j.transci.2022.103520 |